|
| Oncothyreon Files Investigational New Drug Application For PX-866 Oncology Compound |
5 May 08, 14:11 |
|
| Oncothyreon Inc. recently announced that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration for PX-866, a small molecule phosphatidylinositol-3-kinase (PI-3-kinase) inhibitor for the treatment of advanced cancers. Following FDA review, Oncothyreon plans to initiate a Phase 1 clinical trial of PX-866. |
| more |
|
